{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T12:26:39Z","timestamp":1772886399137,"version":"3.50.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,12,28]],"date-time":"2024-12-28T00:00:00Z","timestamp":1735344000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,28]],"date-time":"2024-12-28T00:00:00Z","timestamp":1735344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Funds of China","doi-asserted-by":"crossref","award":["82174229"],"award-info":[{"award-number":["82174229"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Funds of China","doi-asserted-by":"crossref","award":["82174229"],"award-info":[{"award-number":["82174229"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Funds of China","doi-asserted-by":"crossref","award":["82174229"],"award-info":[{"award-number":["82174229"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Funds of China","doi-asserted-by":"crossref","award":["82174229"],"award-info":[{"award-number":["82174229"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Funds of China","doi-asserted-by":"crossref","award":["82174229"],"award-info":[{"award-number":["82174229"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Funds of China","doi-asserted-by":"crossref","award":["82174229"],"award-info":[{"award-number":["82174229"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Funds of China","doi-asserted-by":"crossref","award":["82174229"],"award-info":[{"award-number":["82174229"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFC3502000"],"award-info":[{"award-number":["2022YFC3502000"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFC3502000"],"award-info":[{"award-number":["2022YFC3502000"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFC3502000"],"award-info":[{"award-number":["2022YFC3502000"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFC3502000"],"award-info":[{"award-number":["2022YFC3502000"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFC3502000"],"award-info":[{"award-number":["2022YFC3502000"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFC3502000"],"award-info":[{"award-number":["2022YFC3502000"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFC3502000"],"award-info":[{"award-number":["2022YFC3502000"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s00228-024-03797-0","type":"journal-article","created":{"date-parts":[[2024,12,28]],"date-time":"2024-12-28T09:02:53Z","timestamp":1735376573000},"page":"383-393","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Quantitative evaluation of the efficacy and safety of first-line systemic therapies for advanced hepatocellular carcinoma"],"prefix":"10.1007","volume":"81","author":[{"given":"Xinrui","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jihan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yixiao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lijuan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruifen","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingshan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lujin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,12,28]]},"reference":[{"issue":"15","key":"3797_CR1","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1056\/NEJMra1713263","volume":"380","author":"A Villanueva","year":"2019","unstructured":"Villanueva A (2019) Hepatocellular carcinoma. N Engl J Med 380(15):1450\u20131462","journal-title":"N Engl J Med"},{"issue":"6","key":"3797_CR2","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1053\/j.gastro.2019.12.053","volume":"158","author":"R Loomba","year":"2020","unstructured":"Loomba R, Lim JK, Patton H et al (2020) AGA clinical practice update on screening and surveillance for hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: expert review. Gastroenterology 158(6):1822\u20131830","journal-title":"Gastroenterology"},{"issue":"1","key":"3797_CR3","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","volume":"7","author":"JM Llovet","year":"2021","unstructured":"Llovet JM, Kelley RK, Villanueva A et al (2021) Hepatocellular carcinoma. Nat Rev Dis Primers 7(1):6","journal-title":"Nat Rev Dis Primers"},{"issue":"Suppl 1","key":"3797_CR4","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1159\/000111705","volume":"72","author":"RW Pang","year":"2007","unstructured":"Pang RW, Poon RT (2007) From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now. Oncology 72(Suppl 1):30\u201344","journal-title":"Oncology"},{"issue":"4","key":"3797_CR5","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359(4):378\u2013390","journal-title":"N Engl J Med"},{"issue":"20","key":"3797_CR6","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M et al (2020) Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med 382(20):1894\u20131905","journal-title":"N Engl J Med"},{"issue":"1","key":"3797_CR7","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S1470-2045(21)00604-5","volume":"23","author":"T Yau","year":"2022","unstructured":"Yau T, Park JW, Finn RS et al (2022) Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol 23(1):77\u201390","journal-title":"Lancet Oncol"},{"issue":"12","key":"3797_CR8","doi-asserted-by":"publisher","first-page":"2547","DOI":"10.1158\/1078-0432.CCR-21-3807","volume":"28","author":"G Verset","year":"2022","unstructured":"Verset G, Borbath I, Karwal M et al (2022) Pembrolizumab monotherapy for previously untreated advanced hepatocellular carcinoma: data from the open-label, phase II KEYNOTE-224 trial. Clin Cancer Res 28(12):2547\u20132554","journal-title":"Clin Cancer Res"},{"key":"3797_CR9","doi-asserted-by":"publisher","unstructured":"Abou-Alfa GK, Lau G, Kudo M et al (2022) Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evid 1(8). https:\/\/doi.org\/10.1056\/EVIDoa2100070","DOI":"10.1056\/EVIDoa2100070"},{"key":"3797_CR10","doi-asserted-by":"publisher","first-page":"145","DOI":"10.2147\/JHC.S268305","volume":"8","author":"R Park","year":"2021","unstructured":"Park R, Lopes da Silva L, Nissaisorakarn V et al (2021) Comparison of efficacy of systemic therapies in advanced hepatocellular carcinoma: updated systematic review and frequentist network meta-analysis of randomized controlled trials. J Hepatocell Carcinoma 8:145\u201354","journal-title":"J Hepatocell Carcinoma"},{"issue":"1","key":"3797_CR11","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1159\/000526639","volume":"12","author":"KY Fong","year":"2023","unstructured":"Fong KY, Zhao JJ, Sultana R et al (2023) First-line systemic therapies for advanced hepatocellular carcinoma: a systematic review and patient-level network meta-analysis. Liver Cancer 12(1):7\u201318","journal-title":"Liver Cancer"},{"issue":"12","key":"3797_CR12","doi-asserted-by":"publisher","first-page":"e204930","DOI":"10.1001\/jamaoncol.2020.4930","volume":"6","author":"MB Sonbol","year":"2020","unstructured":"Sonbol MB, Riaz IB, Naqvi SAA et al (2020) Systemic therapy and sequencing options in advanced hepatocellular carcinoma: a systematic review and network meta-analysis. JAMA Oncol 6(12):e204930","journal-title":"JAMA Oncol"},{"issue":"3","key":"3797_CR13","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/clpt.2012.122","volume":"92","author":"DR Mould","year":"2012","unstructured":"Mould DR (2012) Model-based meta-analysis: an important tool for making quantitative decisions during drug development. Clin Pharmacol Ther 92(3):283\u2013286","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"3797_CR14","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1002\/cpt.1462","volume":"106","author":"VV Upreti","year":"2019","unstructured":"Upreti VV, Venkatakrishnan K (2019) Model-based meta-analysis: optimizing research, development, and utilization of therapeutics using the totality of evidence. Clin Pharmacol Ther 106(5):981\u2013992","journal-title":"Clin Pharmacol Ther"},{"key":"3797_CR15","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:l4898","journal-title":"BMJ"},{"key":"3797_CR16","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.jclinepi.2018.01.012","volume":"111","author":"HJ Sch\u00fcnemann","year":"2019","unstructured":"Sch\u00fcnemann HJ, Cuello C, Akl EA et al (2019) GRADE guidelines: 18. How ROBINS-I and other tools to assess risk of bias in nonrandomized studies should be used to rate the certainty of a body of evidence. J Clin Epidemiol 111:105\u2013114","journal-title":"J Clin Epidemiol"},{"issue":"5","key":"3797_CR17","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nrclinonc.2018.29","volume":"15","author":"D Fukumura","year":"2018","unstructured":"Fukumura D, Kloepper J, Amoozgar Z et al (2018) Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat Rev Clin Oncol 15(5):325\u2013340","journal-title":"Nat Rev Clin Oncol"},{"issue":"18","key":"3797_CR18","doi-asserted-by":"publisher","first-page":"4749","DOI":"10.1073\/pnas.1718217115","volume":"115","author":"E Ahn","year":"2018","unstructured":"Ahn E, Araki K, Hashimoto M et al (2018) Role of PD-1 during effector CD8 T cell differentiation. Proc Natl Acad Sci U S A 115(18):4749\u20134754","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"3797_CR19","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/s41571-021-00496-y","volume":"18","author":"ZR Huinen","year":"2021","unstructured":"Huinen ZR, Huijbers EJM, van Beijnum JR et al (2021) Anti-angiogenic agents - overcoming tumour endothelial cell anergy and improving immunotherapy outcomes. Nat Rev Clin Oncol 18(8):527\u2013540","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"3797_CR20","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s12072-020-10064-8","volume":"14","author":"Q Rao","year":"2020","unstructured":"Rao Q, Li M, Xu W et al (2020) Clinical benefits of PD-1\/PD-L1 inhibitors in advanced hepatocellular carcinoma: a systematic review and meta-analysis. Hepatol Int 14(5):765\u2013775","journal-title":"Hepatol Int"},{"key":"3797_CR21","doi-asserted-by":"publisher","first-page":"108135","DOI":"10.1016\/j.intimp.2021.108135","volume":"100","author":"H Xu","year":"2021","unstructured":"Xu H, Cao D, Zheng Y et al (2021) Potential predictors for survival in hepatocellular carcinoma patients treated with immune checkpoint inhibitors: a meta-analysis. Int Immunopharmacol 100:108135","journal-title":"Int Immunopharmacol"},{"key":"3797_CR22","doi-asserted-by":"publisher","first-page":"109244","DOI":"10.1016\/j.intimp.2022.109244","volume":"112","author":"J Zheng","year":"2022","unstructured":"Zheng J, Shao M, Yang W et al (2022) Benefits of combination therapy with immune checkpoint inhibitors and predictive role of tumour mutation burden in hepatocellular carcinoma: a systematic review and meta-analysis. Int Immunopharmacol 112:109244","journal-title":"Int Immunopharmacol"},{"issue":"5","key":"3797_CR23","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1080\/21645515.2019.1571892","volume":"15","author":"Y Jiang","year":"2019","unstructured":"Jiang Y, Chen M, Nie H et al (2019) PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations. Hum Vaccin Immunother 15(5):1111\u20131122","journal-title":"Hum Vaccin Immunother"},{"issue":"11","key":"3797_CR24","doi-asserted-by":"publisher","first-page":"7746","DOI":"10.4049\/jimmunol.175.11.7746","volume":"175","author":"AV Maker","year":"2005","unstructured":"Maker AV, Attia P, Rosenberg SA (2005) Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade. J Immunol 175(11):7746\u20137754","journal-title":"J Immunol"},{"issue":"6","key":"3797_CR25","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1159\/000503254","volume":"8","author":"M Kudo","year":"2019","unstructured":"Kudo M (2019) Scientific rationale for combination immunotherapy of hepatocellular carcinoma with Anti-PD-1\/PD-L1 and Anti-CTLA-4 antibodies. Liver Cancer 8(6):413\u2013426","journal-title":"Liver Cancer"},{"issue":"5","key":"3797_CR26","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1002\/psp4.12078","volume":"5","author":"ML Zierhut","year":"2016","unstructured":"Zierhut ML, Chen Y, Pithavala YK et al (2016) Clinical trial simulations from a model-based meta-analysis of studies in patients with advanced hepatocellular carcinoma receiving antiangiogenic therapy. CPT Pharmacometrics Syst Pharmacol 5(5):274\u2013282","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"4","key":"3797_CR27","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.jhep.2021.07.004","volume":"75","author":"J Bruix","year":"2021","unstructured":"Bruix J, Chan SL, Galle PR et al (2021) Systemic treatment of hepatocellular carcinoma: an EASL position paper. J Hepatol 75(4):960\u2013974","journal-title":"J Hepatol"},{"issue":"5","key":"3797_CR28","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1002\/psp4.12299","volume":"7","author":"M Boucher","year":"2018","unstructured":"Boucher M, Bennetts M (2018) Many flavors of model-based meta-analysis: part II - modeling summary level longitudinal responses. CPT Pharmacometrics Syst Pharmacol 7(5):288\u2013297","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"10126","key":"3797_CR29","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"Kudo M, Finn RS, Qin S et al (2018) Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 391(10126):1163\u20131173","journal-title":"Lancet"},{"issue":"3","key":"3797_CR30","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41571-021-00573-2","volume":"19","author":"JM Llovet","year":"2022","unstructured":"Llovet JM, Castet F, Heikenwalder M et al (2022) Immunotherapies for hepatocellular carcinoma. Nat Rev Clin Oncol 19(3):151\u2013172","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"3797_CR31","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/j.jhep.2021.05.015","volume":"75","author":"R Kolamunnage-Dona","year":"2021","unstructured":"Kolamunnage-Dona R, Berhane S, Potts H et al (2021) Sorafenib is associated with a reduced rate of tumour growth and liver function deterioration in HCV-induced hepatocellular carcinoma. J Hepatol 75(4):879\u2013887","journal-title":"J Hepatol"},{"issue":"29","key":"3797_CR32","doi-asserted-by":"publisher","first-page":"3411","DOI":"10.2217\/fon-2019-0287","volume":"15","author":"G Cabibbo","year":"2019","unstructured":"Cabibbo G, Cucchetti A, Camm\u00e0 C et al (2019) Outcomes of hepatocellular carcinoma patients treated with sorafenib: a meta-analysis of Phase III trials. Future Oncol 15(29):3411\u20133422","journal-title":"Future Oncol"},{"issue":"8","key":"3797_CR33","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1111\/liv.14877","volume":"41","author":"DQ Huang","year":"2021","unstructured":"Huang DQ, Hoang JK, Leong J et al (2021) Differential characteristics and outcomes of Asian and non-Asian patients with HBV-related hepatocellular carcinoma. Liver Int 41(8):1922\u20131932","journal-title":"Liver Int"},{"issue":"8","key":"3797_CR34","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1200\/JCO.2013.52.9651","volume":"33","author":"Z Ren","year":"2015","unstructured":"Ren Z, Zhu K, Kang H et al (2015) Randomized controlled trial of the prophylactic effect of urea-based cream on sorafenib-associated hand-foot skin reactions in patients with advanced hepatocellular carcinoma. J Clin Oncol 33(8):894\u2013900","journal-title":"J Clin Oncol"},{"issue":"6","key":"3797_CR35","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1002\/hep.24644","volume":"54","author":"M Iavarone","year":"2011","unstructured":"Iavarone M, Cabibbo G, Piscaglia F et al (2011) Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy. Hepatology 54(6):2055\u20132063","journal-title":"Hepatology"},{"issue":"5","key":"3797_CR36","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1002\/hep.29668","volume":"67","author":"EG Giannini","year":"2018","unstructured":"Giannini EG, Bucci L, Garuti F et al (2018) Patients with advanced hepatocellular carcinoma need a personalized management: a lesson from clinical practice. Hepatology 67(5):1784\u20131796","journal-title":"Hepatology"},{"key":"3797_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2018.09.031","volume":"105","author":"MG McNamara","year":"2018","unstructured":"McNamara MG, Slagter AE, Nuttall C et al (2018) Sorafenib as first-line therapy in patients with advanced Child-Pugh B hepatocellular carcinoma-a meta-analysis. Eur J Cancer 105:1\u20139","journal-title":"Eur J Cancer"},{"issue":"4","key":"3797_CR38","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.jhep.2021.07.014","volume":"75","author":"PR Galle","year":"2021","unstructured":"Galle PR, Abou-Alfa GK (2021) Decision making in systemic therapy of hepatocellular carcinoma: should we pay attention to disease aetiology? J Hepatol 75(4):763\u2013764","journal-title":"J Hepatol"},{"issue":"2","key":"3797_CR39","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.jhep.2018.10.008","volume":"70","author":"N Ganne-Carri\u00e9","year":"2019","unstructured":"Ganne-Carri\u00e9 N, Nahon P (2019) Hepatocellular carcinoma in the setting of alcohol-related liver disease. J Hepatol 70(2):284\u2013293","journal-title":"J Hepatol"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-024-03797-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-024-03797-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-024-03797-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T07:11:58Z","timestamp":1739430718000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-024-03797-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,28]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["3797"],"URL":"https:\/\/doi.org\/10.1007\/s00228-024-03797-0","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,28]]},"assertion":[{"value":"21 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}